Source:
Source:
Source:
Source:
Source:Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Stem Cell Therapy
'Praise' for California Stem Cell Agency from Unlikely Corner
Posted: April 30, 2013 at 5:39 pm
The California stem cell agency this
month received what some might consider a gesture of approval from a
longtime foe – LifeNews.com.
LifeNews is a site devoted to
anti-abortion efforts and information and is sharply opposed to research
involving human embryonic stem cells.
anti-abortion efforts and information and is sharply opposed to research
involving human embryonic stem cells.
So it was with some surprise that we
read a tacit endorsement of recent CIRM activities in an April 22 piece written by Gene Tame out of Sacramento. It said the most recent
$32 million grant round from CIRM “demonstrates – again – where
the future of stem cell reserch lies.”
read a tacit endorsement of recent CIRM activities in an April 22 piece written by Gene Tame out of Sacramento. It said the most recent
$32 million grant round from CIRM “demonstrates – again – where
the future of stem cell reserch lies.”
Tame wrote,
“CIRM has been steadily moving away
from its original mission to give preferential
treatment to funding for human embryonic stem cell research
(hESCR). Instead, after adopting a renewed
emphasis on translating research into clinical trials, CIRM
has more and more shifted the bulk of its grants towards funding
research utilizing adult stem cells and other alternatives to hESCR,
such as induced
pluripotent stem cells (iPSCs).”
Tame continued,
“(T)he lack, once again, of funding
for hESCR only serves to highlight how old and dated that approach to
finding treatments and cures increasingly seems.”
Tame is correct in his assertion that
the stem cell agency has moved a considerable distance from its
reason for being – research involving human embryonic stem cells.
In 2004, the ballot campaign to create the agency pitched voters hard
on hESC research and made no real mention of adult stem cells.
Instead, it focused on the threat from the Bush Administration with its
restrictions on hESC research, which have been lifted by the Obama
Administration. .
the stem cell agency has moved a considerable distance from its
reason for being – research involving human embryonic stem cells.
In 2004, the ballot campaign to create the agency pitched voters hard
on hESC research and made no real mention of adult stem cells.
Instead, it focused on the threat from the Bush Administration with its
restrictions on hESC research, which have been lifted by the Obama
Administration. .
In 2010, a study by a Georgia Tech
academic, Aaron Levine, reported that through 2009 only 18 percent of California's dollars went for grants that were "clearly" not eligible for federal funding under the Bush restrictions.
academic, Aaron Levine, reported that through 2009 only 18 percent of California's dollars went for grants that were "clearly" not eligible for federal funding under the Bush restrictions.
At the date of the study, CIRM had not
publicly disclosed statistics on its funding of hESC research.
publicly disclosed statistics on its funding of hESC research.
Today, however, its web site shows that only about 240 of the 595 awards that it has handed out are going for hESC research. CIRM has not made public the dollar value of
those 240 awards, but it has given away a total of $1.8 billion. (Following publication of this item, the agency told the California Stem Report that it has funded $458 million in hESC research.)
those 240 awards, but it has given away a total of $1.8 billion. (Following publication of this item, the agency told the California Stem Report that it has funded $458 million in hESC research.)
A footnote: Levine was a member of the
blue-ribbon Institute of Medicine panel that recommended sweeping
changes at CIRM.
blue-ribbon Institute of Medicine panel that recommended sweeping
changes at CIRM.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on 'Praise' for California Stem Cell Agency from Unlikely Corner
Clarifying the effect of stem cell therapy on cancer
Posted: April 28, 2013 at 9:45 pm
Public release date: 28-Apr-2013 [ | E-mail | Share ]
Contact: Hilary Glover hilary.glover@biomedcentral.com 44-020-319-22370 BioMed Central
Injection of human stem cells into mice with tumors slowed down tumor growth, finds research published in BioMed Central's open access journal Stem Cell Research & Therapy. Human mesenchymal stem cells (MSC), isolated from bone marrow, caused changes in blood vessels supplying the tumor, and it is this modification of blood supply which seems to impact tumor growth.
The use of stem cells in treating cancer has been controversial, with some studies finding that stem cells force tumors to enter programmed cell death. However other studies find that stem cells actually promote tumor growth by inducing infiltration of new blood vessels. In attempting to sort out this puzzle researchers from INSERM groups at Universit Joseph Fourier in collaboration with CHU de Grenoble investigated the impact of MSC on already established subcutaneous or lung metastasis in mice.
For both the subcutaneous and lung tumors, injection of MSC reduced cell division, consequently slowing the rate of tumor growth. Part of the mode of action of stem cells therefore appears to be due to with angiogenesis, but the mechanism behind this is still unclear.
Claire Rome who led this study explained, "We found that MSC altered vasculature inside the tumor - although new blood vessels were generated, overall they were longer and fewer than in untreated tumors. This could be restricting the oxygen and nutrients to the tumor, limiting cell division." She continued, "Our study confirms others which propose that stem cells, in particular MSC, might be one way forwards in treating cancer."
Commenting on this study Celia Gomes, from the University of Coimbra, said, "One of the interesting questions this study raises is when MSC promote tumor growth and when they restrict it. The answer seems to be timing this study looks at already established tumors, while others, which find that MSC increase growth, tend to be investigating new tumors. This is a first step in the path to identifying exactly which patients might benefit from stem cell therapy and who will not."
###
Media Contact
Dr Hilary Glover Scientific Press Officer, BioMed Central Tel: +44 (0) 20 3192 2370 Mob: +44 (0) 778 698 1967 Email: hilary.glover@biomedcentral.com
View post:
Clarifying the effect of stem cell therapy on cancer
Posted in Stem Cell Therapy
Comments Off on Clarifying the effect of stem cell therapy on cancer
California Stem Cell Agency Seeks Lobbyist Bids
Posted: April 28, 2013 at 3:10 am
The California stem cell agency has put
out a bid for a private lobbyist to watch out for its interests in
Sacramento, perhaps severing a longtime relationship with one of the
Capitol's more prestigious power brokers.
out a bid for a private lobbyist to watch out for its interests in
Sacramento, perhaps severing a longtime relationship with one of the
Capitol's more prestigious power brokers.
The $3 billion agency has had
a contract since 2005 with Nielsen Merksamer Parrinello Gross &
Leoni LLP of Sacramento, which reported lobbying revenue last
year of more than $5 million. That made it one of the top revenue producers among California lobbyists.
a contract since 2005 with Nielsen Merksamer Parrinello Gross &
Leoni LLP of Sacramento, which reported lobbying revenue last
year of more than $5 million. That made it one of the top revenue producers among California lobbyists.
The agency's contract is tiny, however.
It started at $49,900 for five months in 2005 on a no-bid contract with Nielsen, although the annual figure is now $49,999. The agency's request this month for bids calls for a boost to $65,000 annually.
It started at $49,900 for five months in 2005 on a no-bid contract with Nielsen, although the annual figure is now $49,999. The agency's request this month for bids calls for a boost to $65,000 annually.
Nielsen Merksamer is very active in
health care lobbying. Its biotech/pharmaceutical clients have included Genentech, Merck &
Co. and Pfizer. The firm also played a role in the drafting of and
campaign for Proposition 71 in 2004. In 2009, at the behest of
Robert Klein, then chairman of the agency, it produced a legal memo
that Klein used to help box in the agency governing board on taking a
position on the Little Hoover Commission report recommending major
changes at the enterprise.
health care lobbying. Its biotech/pharmaceutical clients have included Genentech, Merck &
Co. and Pfizer. The firm also played a role in the drafting of and
campaign for Proposition 71 in 2004. In 2009, at the behest of
Robert Klein, then chairman of the agency, it produced a legal memo
that Klein used to help box in the agency governing board on taking a
position on the Little Hoover Commission report recommending major
changes at the enterprise.
The stem cell agency is one of the few
agencies that hires a private lobbyist, which has raised some
eyebrows. Nearly all agencies handle legislative relations
internally.
agencies that hires a private lobbyist, which has raised some
eyebrows. Nearly all agencies handle legislative relations
internally.
Deadline for bids is May 3.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/0HfVYv0XVQg/california-stem-cell-agency-seeks.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on California Stem Cell Agency Seeks Lobbyist Bids
Stem Cell Agency Provides More Cost Detail on Future Plans
Posted: April 28, 2013 at 3:10 am
The California stem cell agency today clarified the size of the assumed "public investment" in its rough outline of its plan for future activities.
In response to a query from the California Stem Cell Report, Don Gibbons, a spokesman for the agency, said,
"This hypothetical range of public investment ($50 million to $200 million) is thought of as a one-time investment, with hope of private investments in multiples of that with the fund recharging to some extent based on revenue."
Gibbons also said the agency did not want to indicate what it was prepared to pay for the study. He said,
"We have not wanted to post the budget range because we want honest estimates of what folks think the budget should be rather than having them penciling estimates that max out the budget."
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Stem Cell Agency Provides More Cost Detail on Future Plans
Deadline This October: California Stem Cell Agency Seeking Detailed Public-Private Plan for its Future
Posted: April 28, 2013 at 3:10 am
The $3 billion California stem cell
agency, which is currently scheduled to go out of business in a few
years, hopes to come up with a detailed plan by this fall for a novel
public-private arrangement that would extend its life.
The rough outlines of the proposal
assume $50 to $200 million in “public investment,” although it is
not clear whether that would be a one-time figure or an annual amount
from presumably the state budget or perhaps another state bond
measure. The concept includes additional private funding of a
yet-to-be-determined nature. (The agency later said that the public investment figures would be a one-time event.)
assume $50 to $200 million in “public investment,” although it is
not clear whether that would be a one-time figure or an annual amount
from presumably the state budget or perhaps another state bond
measure. The concept includes additional private funding of a
yet-to-be-determined nature. (The agency later said that the public investment figures would be a one-time event.)
The broad sketch of the agency's latest
thinking about how to regenerate itself was found in an RFP posted four days ago on its website.
thinking about how to regenerate itself was found in an RFP posted four days ago on its website.
CIRM is seeking a consultant who would
flesh out the general concepts that it has offered. Work would
begin in mid June and be completed in four months, close to the ninth
anniversary of the agency, formally known as the California
Institute for Regenerative Medicine. The RFP did not contain a figure
for the cost of the study, but said that the price would be part of
the criteria for evaluating bids.
flesh out the general concepts that it has offered. Work would
begin in mid June and be completed in four months, close to the ninth
anniversary of the agency, formally known as the California
Institute for Regenerative Medicine. The RFP did not contain a figure
for the cost of the study, but said that the price would be part of
the criteria for evaluating bids.
CIRM was created in November 2004 when
California voters approved Proposition 71, a ballot initiative. Since
then it has awarded $1.8 billion to 595 recipients. It is funded by
money borrowed by the state (bonds), but cash for new grants is
scheduled to run out in 2017. Interests costs on the bonds raise the
total cost of the agency to roughly $6 billion.
California voters approved Proposition 71, a ballot initiative. Since
then it has awarded $1.8 billion to 595 recipients. It is funded by
money borrowed by the state (bonds), but cash for new grants is
scheduled to run out in 2017. Interests costs on the bonds raise the
total cost of the agency to roughly $6 billion.
CIRM said in the RFP that the plan for
its future should provide
its future should provide
“...an in-depth analysis of various
public-private funding models with potential to attract private
sector investment to, and facilitate further development of the most
promising CIRM-supported research projects; and recommend a single
preferred approach for achieving this goal, complete with details
relating to the recommended structure and an operational plan.”
The RFP also contained a just-released,
$31,750 study by CBT Advisors of Cambridge, Mass, that examined
mechanisms for financing translational research, which is the key
focus nowadays at the stem cell agency. Such research is aimed at
pushing laboratory findings into the marketplace.
$31,750 study by CBT Advisors of Cambridge, Mass, that examined
mechanisms for financing translational research, which is the key
focus nowadays at the stem cell agency. Such research is aimed at
pushing laboratory findings into the marketplace.
Among other things, the CBT report,
whose lead author was Steve Dickman, said,
whose lead author was Steve Dickman, said,
“The nature of CIRM as a state agency
is perhaps the biggest weak point (and) has to be addressed politically
and cleared up as soon as possible or raising money will be
unnecessarily challenging.”
The CBT study did not address how that
might be done, which could be a considerable task. Proposition 71
modified the state constitution and state law and can be altered only
by a super, super majority vote of the legislature or by another
ballot initiative.
might be done, which could be a considerable task. Proposition 71
modified the state constitution and state law and can be altered only
by a super, super majority vote of the legislature or by another
ballot initiative.
California is the first state to
provide billions for stem cell research by using borrowed money. It
also is unique in California state government in that its funding
flows directly to the agency and cannot be altered by the governor or
the legislature.
provide billions for stem cell research by using borrowed money. It
also is unique in California state government in that its funding
flows directly to the agency and cannot be altered by the governor or
the legislature.
Translating all that into some sort of
public-private arrangement would be novel among state government
departments and could well require legislative or voter approval.
public-private arrangement would be novel among state government
departments and could well require legislative or voter approval.
The California Stem Cell Report has
queried the agency concerning the frequency of the assumed “public
investment” and CIRM's budget for the RFP. We will report that
information when we receive it. (The agency later declined to disclose what it was prepared to pay for the study.)
queried the agency concerning the frequency of the assumed “public
investment” and CIRM's budget for the RFP. We will report that
information when we receive it. (The agency later declined to disclose what it was prepared to pay for the study.)
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Deadline This October: California Stem Cell Agency Seeking Detailed Public-Private Plan for its Future
MS Stem Cell Therapy – Part 1 – Video
Posted: April 27, 2013 at 9:42 am
MS Stem Cell Therapy - Part 1
Over the last decade a Canadian team has been working on a ground breaking stem cell therapy their research has yet to be published, but the patients who hav...
By: GlobalToronto
Read more:
MS Stem Cell Therapy - Part 1 - Video
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on MS Stem Cell Therapy – Part 1 – Video
California Stem Cell Agency Seeks Lobbyist Bids
Posted: April 26, 2013 at 4:54 pm
The California stem cell agency has put
out a bid for a private lobbyist to watch out for its interests in
Sacramento, perhaps severing a longtime relationship with one of the
Capitol's more prestigious power brokers.
out a bid for a private lobbyist to watch out for its interests in
Sacramento, perhaps severing a longtime relationship with one of the
Capitol's more prestigious power brokers.
The $3 billion agency has had
a contract since 2005 with Nielsen Merksamer Parrinello Gross &
Leoni LLP of Sacramento, which reported lobbying revenue last
year of more than $5 million. That made it one of the top revenue producers among California lobbyists.
a contract since 2005 with Nielsen Merksamer Parrinello Gross &
Leoni LLP of Sacramento, which reported lobbying revenue last
year of more than $5 million. That made it one of the top revenue producers among California lobbyists.
The agency's contract is tiny, however.
It started at $49,900 for five months in 2005 on a no-bid contract with Nielsen, although the annual figure is now $49,999. The agency's request this month for bids calls for a boost to $65,000 annually.
It started at $49,900 for five months in 2005 on a no-bid contract with Nielsen, although the annual figure is now $49,999. The agency's request this month for bids calls for a boost to $65,000 annually.
Nielsen Merksamer is very active in
health care lobbying. Its biotech/pharmaceutical clients have included Genentech, Merck &
Co. and Pfizer. The firm also played a role in the drafting of and
campaign for Proposition 71 in 2004. In 2009, at the behest of
Robert Klein, then chairman of the agency, it produced a legal memo
that Klein used to help box in the agency governing board on taking a
position on the Little Hoover Commission report recommending major
changes at the enterprise.
health care lobbying. Its biotech/pharmaceutical clients have included Genentech, Merck &
Co. and Pfizer. The firm also played a role in the drafting of and
campaign for Proposition 71 in 2004. In 2009, at the behest of
Robert Klein, then chairman of the agency, it produced a legal memo
that Klein used to help box in the agency governing board on taking a
position on the Little Hoover Commission report recommending major
changes at the enterprise.
The stem cell agency is one of the few
agencies that hires a private lobbyist, which has raised some
eyebrows. Nearly all agencies handle legislative relations
internally.
agencies that hires a private lobbyist, which has raised some
eyebrows. Nearly all agencies handle legislative relations
internally.
Deadline for bids is May 3.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/0HfVYv0XVQg/california-stem-cell-agency-seeks.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on California Stem Cell Agency Seeks Lobbyist Bids
Stem Cell Therapy Market in Asia-Pacific to 2018 – Commercialization Supported by Favorable Government Policies …
Posted: April 24, 2013 at 2:41 pm
NEW YORK, April 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity
Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity
Summary
GBI Research, the leading business intelligence provider, has released its latest research "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity". The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals' JR-031 (2014) in Japan and FCB Pharmicell's Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.
Scope
- Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore - In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers. - Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. - Key drivers and restraints that have a significant impact on the market. - Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost - Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.
Continued here:
Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies ...
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on Stem Cell Therapy Market in Asia-Pacific to 2018 – Commercialization Supported by Favorable Government Policies …
Stem Cell Agency Provides More Cost Detail on Future Plans
Posted: April 23, 2013 at 7:58 pm
The California stem cell agency today clarified the size of the assumed "public investment" in its rough outline of its plan for future activities.
In response to a query from the California Stem Cell Report, Don Gibbons, a spokesman for the agency, said,
"This hypothetical range of public investment ($50 million to $200 million) is thought of as a one-time investment, with hope of private investments in multiples of that with the fund recharging to some extent based on revenue."
Gibbons also said the agency did not want to indicate what it was prepared to pay for the study. He said,
"We have not wanted to post the budget range because we want honest estimates of what folks think the budget should be rather than having them penciling estimates that max out the budget."
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Stem Cell Agency Provides More Cost Detail on Future Plans
Deadline This October: California Stem Cell Agency Seeking Detailed Public-Private Plan for its Future
Posted: April 23, 2013 at 7:00 pm
The $3 billion California stem cell
agency, which is currently scheduled to go out of business in a few
years, hopes to come up with a detailed plan by this fall for a novel
public-private arrangement that would extend its life.
The rough outlines of the proposal
assume $50 to $200 million in “public investment,” although it is
not clear whether that would be a one-time figure or an annual amount
from presumably the state budget or perhaps another state bond
measure. The concept includes additional private funding of a
yet-to-be-determined nature. (The agency later said that the public investment figures would be a one-time event.)
assume $50 to $200 million in “public investment,” although it is
not clear whether that would be a one-time figure or an annual amount
from presumably the state budget or perhaps another state bond
measure. The concept includes additional private funding of a
yet-to-be-determined nature. (The agency later said that the public investment figures would be a one-time event.)
The broad sketch of the agency's latest
thinking about how to regenerate itself was found in an RFP posted four days ago on its website.
thinking about how to regenerate itself was found in an RFP posted four days ago on its website.
CIRM is seeking a consultant who would
flesh out the general concepts that it has offered. Work would
begin in mid June and be completed in four months, close to the ninth
anniversary of the agency, formally known as the California
Institute for Regenerative Medicine. The RFP did not contain a figure
for the cost of the study, but said that the price would be part of
the criteria for evaluating bids.
flesh out the general concepts that it has offered. Work would
begin in mid June and be completed in four months, close to the ninth
anniversary of the agency, formally known as the California
Institute for Regenerative Medicine. The RFP did not contain a figure
for the cost of the study, but said that the price would be part of
the criteria for evaluating bids.
CIRM was created in November 2004 when
California voters approved Proposition 71, a ballot initiative. Since
then it has awarded $1.8 billion to 595 recipients. It is funded by
money borrowed by the state (bonds), but cash for new grants is
scheduled to run out in 2017. Interests costs on the bonds raise the
total cost of the agency to roughly $6 billion.
California voters approved Proposition 71, a ballot initiative. Since
then it has awarded $1.8 billion to 595 recipients. It is funded by
money borrowed by the state (bonds), but cash for new grants is
scheduled to run out in 2017. Interests costs on the bonds raise the
total cost of the agency to roughly $6 billion.
CIRM said in the RFP that the plan for
its future should provide
its future should provide
“...an in-depth analysis of various
public-private funding models with potential to attract private
sector investment to, and facilitate further development of the most
promising CIRM-supported research projects; and recommend a single
preferred approach for achieving this goal, complete with details
relating to the recommended structure and an operational plan.”
The RFP also contained a just-released,
$31,750 study by CBT Advisors of Cambridge, Mass, that examined
mechanisms for financing translational research, which is the key
focus nowadays at the stem cell agency. Such research is aimed at
pushing laboratory findings into the marketplace.
$31,750 study by CBT Advisors of Cambridge, Mass, that examined
mechanisms for financing translational research, which is the key
focus nowadays at the stem cell agency. Such research is aimed at
pushing laboratory findings into the marketplace.
Among other things, the CBT report,
whose lead author was Steve Dickman, said,
whose lead author was Steve Dickman, said,
“The nature of CIRM as a state agency
is perhaps the biggest weak point (and) has to be addressed politically
and cleared up as soon as possible or raising money will be
unnecessarily challenging.”
The CBT study did not address how that
might be done, which could be a considerable task. Proposition 71
modified the state constitution and state law and can be altered only
by a super, super majority vote of the legislature or by another
ballot initiative.
might be done, which could be a considerable task. Proposition 71
modified the state constitution and state law and can be altered only
by a super, super majority vote of the legislature or by another
ballot initiative.
California is the first state to
provide billions for stem cell research by using borrowed money. It
also is unique in California state government in that its funding
flows directly to the agency and cannot be altered by the governor or
the legislature.
provide billions for stem cell research by using borrowed money. It
also is unique in California state government in that its funding
flows directly to the agency and cannot be altered by the governor or
the legislature.
Translating all that into some sort of
public-private arrangement would be novel among state government
departments and could well require legislative or voter approval.
public-private arrangement would be novel among state government
departments and could well require legislative or voter approval.
The California Stem Cell Report has
queried the agency concerning the frequency of the assumed “public
investment” and CIRM's budget for the RFP. We will report that
information when we receive it. (The agency later declined to disclose what it was prepared to pay for the study.)
queried the agency concerning the frequency of the assumed “public
investment” and CIRM's budget for the RFP. We will report that
information when we receive it. (The agency later declined to disclose what it was prepared to pay for the study.)
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Deadline This October: California Stem Cell Agency Seeking Detailed Public-Private Plan for its Future
